IN BRIEF: Convatec shares rise as improves 2023 revenue guidance

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Convatec Group PLC - Reading, England-based medical products and technologies company - Tells annual general meeting that revenue grew 3.1% on an organic basis in the four months to April 30, but decreased by 1.7% on a reported basis, following exits from hospital care activities in 2022. Organic revenue growth in Advanced Wound Care, Ostomy Care and Continence Care is a mid-single digit percentage, while organic revenue is flat in Infusion Care. Increases overall revenue guidance for 2023, expecting it to grow by between 5.0% and 6.5%. Revenue growth guidance was in the range of 4.5% to 6.0% previously. Expects operating profit margin on a constant currency basis to increase to at least 19.7%, compared to 19.5% in 2022.

Current stock price: 223.20 pence each, up 3.7%

12-month change: down 0.8%

Copyright 2023 Alliance News Ltd. All Rights Reserved.